In late 2004, Transgene S.A.
(Euronext:TNG) brought in Philippe Archinard as CEO to refocus the
immunotherapy company. Moving products through the clinic has taken far longer
than he initially projected - he had hoped to have three products in Phase III
trials by YE07 - but management's efforts appear to be finally paying off (see
BioCentury, June 20, 2005).
Last week, Transgene completed
a E152 million ($194.1 million) rights...